J Med Drug Rev 2012;2;19-30 (Review-Artikel in deutscher Sprache) Molecularly targeted therapies have widened considerably the spectrum of medically treatment options for the advanced renal cell carcinoma (RCC). Additionally to cytokines, several anti-VEGF (vascular endothelial growth factor) therapies and inhibitors of the mTOR (mammalian target of rapamycin) pathway are available. […]